Vigonvita Life Sciences' IPO Stabilization Period Ends With No Over-Allotment Exercise

MT NewswiresDec 4 10:15

Wangshan Wangshui-B (02630.HK) concludes stabilization period with no price stabilization actions taken and the overallotment option expired.

Gelonghui December 3rd丨Wangshan Wangshui-B (02630.HK) announced that the stabilization period for the global offering ended on December 3, 2025 (i.e., the 30th day after the deadline for submitting applications in the Hong Kong public offering). There was no over-allotment of H shares in the international offering. The stabilizing price operator or any person acting on its behalf did not undertake any stabilization actions during the stabilization period. The sponsor and overall coordinator (for itself and on behalf of the international underwriters) did not exercise the over-allotment option, and the over-allotment option lapsed on December 3, 2025. Therefore, no H shares were issued by the company pursuant to the over-allotment option.

Gelonghui FinanceDec 3 16:42

Wangshan Wangshui-B (02630.HK) enters into a licensing agreement with Simcere Pharmaceutical for a new indication of Hydrobromide Deuterium Remdesivir (VV116).

Gelonghui, December 3rd丨Wangshan Wangshui-B (02630.HK) announced that the company has entered into a licensing agreement with Simcere Pharmaceutical (02096.HK) for new indications of VV116. Under the agreement, Wangshan Wangshui will grant Simcere Pharmaceutical exclusive licensing rights for VV116 in Greater China for the treatment of Respiratory Syncytial Virus (“RSV”) and Human Metapneumovirus (“HMPV”) infections. By leveraging their respective strengths in research and development, manufacturing, and commercialization, Wangshan Wangshui and Simcere Pharmaceutical aim to accelerate the clinical development and commercialization of VV116, with the goal of benefiting more patients.

Gelonghui FinanceDec 3 16:32

Express News | The newly listed Quantitative School surged nearly 19% with a turnover exceeding HKD 11 million; another newly listed firm, Wangshan Wangshui, rose over 8%, marking a continuous weekly increase.

BreakingsDec 2 11:02

Wangshan Wangshui-B (02630) Proposes Implementation of Full H-share Circulation

Wangshan Wangshui-B (02630) announced that on November 26, 2025, the board of directors considered and approved the proposal to implement the full H-share convertibility plan. Specifically, this involves converting 100 million unlisted shares held by 10 shareholders of the company into H-shares of the company (representing approximately 59.7983% of the total number of issued shares as of the date of this announcement). Upon obtaining all necessary approvals (including filing with the China Securities Regulatory Commission) and compliance with all applicable laws, regulations, and rules, the 100 million unlisted shares will be converted into H-shares. The company will also apply to the Stock Exchange for approval to list and trade these H-shares on the Main Board (the “Conversion and Listing”). According to the company’s articles of association, the Conversion and Listing do not require shareholder approval at a general meeting.

Zhitong FinanceNov 27 16:41

From Summit to Win-Win! Ark Jianke (06086) and Wangshan Wangshui-B (02630) Deepen Strategic Cooperation in the 'AI + Chronic Disease Management' Field, Jointly Building a Digital and Intelligent Future for the Health Industry

This collaboration represents a vivid example of the precise alignment and efficient complementarity between core industry resources and intelligent technology capabilities. Moving forward, the two parties will leverage cooperation in product pipelines and digital marketing as entry points to jointly explore innovative approaches empowered by AI, injecting strong momentum into the high-quality development of the health industry.

Zhitong FinanceNov 26 10:02